Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.

Published on Apr 9, 2021in European Heart Journal - Cardiovascular Pharmacotherapy6.696
· DOI :10.1093/EHJCVP/PVAA116
Giuseppe Gargiulo26
Estimated H-index: 26
(University of Naples Federico II),
Christopher P. Cannon168
Estimated H-index: 168
(Brigham and Women's Hospital)
+ 8 AuthorsMarco Valgimigli117
Estimated H-index: 117
(University of Bern)
Sources
Abstract
AIMS Safety and efficacy of antithrombotic regimens in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI) may differ based on clinical presentation. We sought to comparing double vs. triple antithrombotic therapy (DAT vs TAT) in AF patients with or without acute coronary syndrome (ACS) undergoing PCI. METHODS AND RESULTS A systematic review and meta-analysis was performed using PubMed to search for non-vitamin K antagonist oral anticoagulant (NOAC)-based randomized clinical trials. Data on subgroups of ACS or elective PCI were obtained by published reports or trial investigators. A total of 10,193 patients from 4 NOAC trials were analyzed, of whom 5,675 presenting with ACS (DAT = 3,063 vs. TAT = 2,612) and 4,518 with SCAD (DAT = 2,421 vs. TAT = 2,097). The primary safety endpoint of ISTH major bleeding or CRNMB was reduced with DAT compared with TAT in both ACS (12.2% vs 19.4%; RR 0.63, 95% CI 0.56-0.71; p < 0.0001; I2=0%) and SCAD (14.6% vs 22.0%; RR 0.68, 95% CI 0.55-0.85; p = 0.0008; I2=66%), without interaction (p-int = 0.54). Findings were consistent for secondary bleeding endpoints, including intracranial Haemorrhage. In both subgroups, there was no difference between DAT and TAT for all-cause death, major adverse cardiovascular events, or stroke. Myocardial infarction and stent thrombosis were numerically higher with DAT vs. TAT consistently in ACS and SCAD (p-int = 0.60 and 0.86 respectively). Findings were confirmed by multiple sensitivity analyses, including a separate analysis on dabigatran regimens and a restriction to PCI population. CONCLUSIONS DAT, compared with TAT, is associated with lower bleeding risks, including intracranial Haemorrhage, and a small non-significant excess of cardiac ischaemic events in both patients with or without ACS.
📖 Papers frequently viewed together
20204.04Europace
4 Authors (Mattia Galli, ..., Filippo Crea)
17 Citations
2 Citations
32 Citations
References25
Newest
#1Andrea Rubboli (AUSL: Academy for Urban School Leadership)H-Index: 6
#1Andrea Rubboli (AUSL: Academy for Urban School Leadership)H-Index: 20
Last. Gregory Y.H. Lip (University of Liverpool)H-Index: 195
view all 4 authors...
In accordance with the 2018 joint consensus document issued by the European Heart Rhythm Association (EHRA), European Society of Cardiology (ESC) Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA), and endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA), a...
2 CitationsSource
#1Pascal Vranckx (University of Hasselt)H-Index: 27
#2Marco Valgimigli (University of Bern)H-Index: 117
Last. Andreas GoetteH-Index: 37
view all 13 authors...
Aims To compare the safety and efficacy of edoxaban combined with P2Y12 inhibition following percutaneous coronary intervention (PCI) in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome (ACS) or chronic coronary syndrome (CCS). Methods and results In this pre-specified sub-analysis of the ENTRUST-AF PCI trial, participants were randomly assigned 1:1 to edoxaban- or vitamin K antagonist (VKA)-based strategy and randomization was stratified by ACS (edoxaban n = 388...
9 CitationsSource
#1Davide Capodanno (University of Catania)H-Index: 6
#1Davide Capodanno (University of Catania)H-Index: 74
Last. Dominick J. Angiolillo (UF: University of Florida)H-Index: 106
view all 10 authors...
Background The optimal antithrombotic therapy for patients with atrial fibrillation undergoing percutaneous coronary intervention is a topic of debate. We aimed at defining the efficacy and safety ...
13 CitationsSource
#1Giuseppe Gargiulo (University of Naples Federico II)H-Index: 26
#2Andreas GoetteH-Index: 37
Last. Marco Valgimigli (University of Bern)H-Index: 117
view all 4 authors...
3 CitationsSource
#1Renato D. Lopes (Duke University)H-Index: 87
#2Hwanhee Hong (Duke University)H-Index: 13
Last. John H. Alexander (Duke University)H-Index: 81
view all 15 authors...
Importance Antithrombotic treatment in patients with atrial fibrillation (AF) and percutaneous coronary intervention (PCI) presents a balancing act with regard to bleeding and ischemic risks. Objectives To evaluate the safety and efficacy of 4 antithrombotic regimens by conducting an up-to-date network meta-analysis and to identify the optimal treatment for patients with AF undergoing PCI. Data Sources Online computerized database (MEDLINE). Study Selection Five randomized studies were included ...
25 CitationsSource
#1Dominick J. Angiolillo (UF: University of Florida)H-Index: 106
#2Davide Capodanno (University of Catania)H-Index: 74
Last. Matthew J. Price (Scripps Health)H-Index: 50
view all 8 authors...
Abstract Objectives The aim of this study was to develop a risk score integrating cytochrome P450 2C19 loss-of-function genotypes with clinical risk factors influencing clopidogrel response that would allow the identification with more precision of subjects at risk for high platelet reactivity (HPR) and adverse clinical outcomes. Background Clopidogrel is the most broadly used platelet P2Y12 inhibitor. However, a considerable number of patients achieve inadequate platelet inhibition, with persis...
24 CitationsSource
#1Giuseppe Gargiulo (University of Naples Federico II)H-Index: 26
#2Andreas GoetteH-Index: 37
Last. Marco Valgimigli (University of Bern)H-Index: 117
view all 7 authors...
AIMS: To investigate the safety and efficacy of double vs. triple antithrombotic therapy (DAT vs. TAT) in patients with atrial fibrillation (AF) and acute coronary syndrome or who underwent percutaneous coronary intervention (PCI). METHODS AND RESULTS: A systematic review and meta-analysis was performed using PubMed to search for non-vitamin K antagonist oral anticoagulant (NOAC)-based randomized clinical trials comparing DAT vs. TAT in AF patients undergoing PCI. Four trials encompassing 10 234...
115 CitationsSource
#1Stephan Windecker (University of Bern)H-Index: 150
#2Renato D. Lopes (Duke University)H-Index: 87
Last. John H. Alexander (Duke University)H-Index: 81
view all 33 authors...
Background: The safety and efficacy of antithrombotic regimens may differ between patients with atrial fibrillation (AF) who have acute coronary syndromes (ACS), treated medically or with percutane...
33 CitationsSource
Non-vitamin k antagonist oral anticoagulants (NOACs) are drugs of choice for the majority of patients with atrial fibrillation (AF) to prevent cerebral strokes (1). The risk for stroke in AF patients is determined by concomitant clinical factors, which are summarized in the CHA2DS2-Vasc risk score (2).
2 CitationsSource
#1Pascal Vranckx (University of Hasselt)H-Index: 27
#2Marco Valgimigli (University of Bern)H-Index: 117
Last. Andreas GoetteH-Index: 37
view all 16 authors...
Summary Background We aimed to assess the safety of edoxaban in combination with P2Y12 inhibition in patients with atrial fibrillation who had percutaneous coronary intervention (PCI). Methods ENTRUST-AF PCI was a randomised, multicentre, open-label, non-inferiority phase 3b trial with masked outcome evaluation, done at 186 sites in 18 countries. Patients had atrial fibrillation requiring oral anticoagulation, were aged at least 18 years, and had a successful PCI for stable coronary artery disea...
233 CitationsSource
Cited By9
Newest
#1Nuccia Morici (University of Milan)H-Index: 18
#2Stefano De Servi (UNIPV: University of Pavia)H-Index: 47
Last. Stefano SavonittoH-Index: 31
view all 10 authors...
Older patients are underrepresented in prospective studies and randomized clinical trials of acute coronary syndromes (ACS). Over the last decade, a few specific trials have been conducted in this population, allowing more evidence-based management. Older adults are a heterogeneous, complex, and high-risk group whose management requires a multidimensional clinical approach beyond coronary anatomic variables. This review focuses on available data informing evidence-based interventional and pharma...
Source
#1Jacopo Marazzato (University of Insubria)H-Index: 6
#2Paolo VerdecchiaH-Index: 79
Last. Fabio Angeli (University of Insubria)H-Index: 46
view all 7 authors...
INTRODUCTION In the treatment of patients with atrial fibrillation (AF) who undergo percutaneous coronary intervention (PCI), it is unclear which combination of antithrombotic drugs is preferable and which is the optimal duration of treatment. AREAS COVERED The authors review the available evidence in this area resulting from single studies and meta-analyses. In the absence of direct head-to-head comparisons between different non-vitamin K oral anticoagulants (NOAC), the authors review the avail...
Source
#1Pedro A. LemosH-Index: 66
#2Patricia O. Guimarães (Albert Einstein Hospital)
Last. Otavio Berwanger (Albert Einstein Hospital)H-Index: 39
view all 4 authors...
Source
#1Mattia Galli (UCSC: Catholic University of the Sacred Heart)H-Index: 9
#2Felicita Andreotti (UCSC: Catholic University of the Sacred Heart)H-Index: 68
Last. Italo Porto (UniGe: University of Genoa)H-Index: 10
view all 5 authors...
3 CitationsSource
#1Giuseppe Gargiulo (University of Naples Federico II)H-Index: 26
#2Christopher P. Cannon (Brigham and Women's Hospital)H-Index: 168
Last. Marco ValgimigliH-Index: 117
view all 6 authors...
Source
#1Jan SteffelH-Index: 35
#2Ronan Collins (Trinity College, Dublin)H-Index: 22
Last. Mark Field (University of Liverpool)H-Index: 4
view all 29 authors...
11 CitationsSource
#1Felix Voll (TUM: Technische Universität München)H-Index: 1
#1Felix Voll (TUM: Technische Universität München)H-Index: 1
Last. Salvatore Cassese (TUM: Technische Universität München)H-Index: 30
view all 5 authors...
INTRODUCTION Despite a timely mechanical reperfusion with primary percutaneous coronary intervention (pPCI) patients presenting with ST-elevation myocardial infarction (STEMI) display an increased risk of adverse cardiovascular events. Several studies have demonstrated that guideline-directed antithrombotic therapy is effective to reduce this risk. However, there is still much to be accomplished to improve antithrombotic therapies in this clinical setting. AREAS COVERED This paper reviews curren...
Source
#1Patrick Sulzgruber (Medical University of Vienna)H-Index: 14
#2Felix Hofer (Medical University of Vienna)H-Index: 2
Last. Alexander Niessner (Medical University of Vienna)H-Index: 32
view all 5 authors...
Source
#1Lisa Riesinger (LMU: Ludwig Maximilian University of Munich)H-Index: 4
#2Claudia Strobl (LMU: Ludwig Maximilian University of Munich)
view all 21 authors...
Background null A regimen of dual (DAT) vs. triple (TAT) antithrombotic therapy reduces bleeding in patients with atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, recent evidence suggests that DAT may be associated with an increased ischemic risk. This raises the question whether DAT rather than TAT should be recommended to AF patients that undergo PCI for acute coronary syndrome (ACS), carrying a particularly high risk of both bleeding and ischemic events, ...
Source